Our research is focused on improving preservation of DCD (donors after cardiac death) liver grafts with machine perfusion. In addition, we are testing for the first time if gene silencing using si-RNAs during machine perfusion preservation could reduce ischemia reperfusion injury. Machine perfusion preservation allows graft viability and may improve transplant logistics by extending the period for organ allocation and transport. It may also be able to “resuscitate” grafts that are initially deemed not transplantable. Through this innovative translational approach our lab is performing experiments that could have a major clinical impact for a widespread and relevant problem. There is potential to increase the pool of livers for transplant, reduce the mortality on the waiting list and reduce morbidity and mortality of thousands patients after liver transplant.
University of Massachusetts – Medical School
The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $255 million in research funding annually, 80 percent of which comes from federal funding sources. The mission of the Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. For more information, visit www.umassmed.edu.